Evofem acquires Solosec from Lupin for up to $84M in contingent consideration

Evofem Biosciences, Inc.

Evofem (OTCQB: EVFM) acquired Solosec (secnidazole) from Lupin Inc.; deal closed July 14, 2024.
Potential total consideration up to $84 million based on future contingent milestones; plus assumption of certain liabilities.
Solosec is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.
Acquisition complements Evofem's women's health portfolio, which includes Phexxi; Evofem also in merger with Aditxt (ADTX).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.